Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Eliem Therapeutics EBITDA Margin 2021-2024 | CLYM

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Eliem Therapeutics (CLYM) over the last 10 years. The current EBITDA margin for Eliem Therapeutics as of June 30, 2024 is .
  
Eliem Therapeutics EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.342B $0.000B
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
Stock Name Country Market Cap PE Ratio
Chesapeake Energy (EXE) United States $11.186B 28.69
Hammerson (HMSND) United Kingdom $2.121B 0.00
American Software (LGTY) United States $0.388B 29.97
Learn CW Investment (INV) United States $0.204B 0.00
Nicholas Financial (OMCC) United States $0.079B 0.00
ExcelFin Acquisition (BDMD) $0.033B 0.00
Caravelle Group (HTCO) Singapore $0.024B 0.00
Recruiter (NIXX) United States $0.007B 0.00